Contribute Try STAT+ Today

In his office at Pfizer’s 42nd Street headquarters in Manhattan, Chief Scientific Officer Mikael Dolsten keeps a chessboard. Dolsten has played since he was a boy in Sweden, but this board has a special provenance: It was a gift from former Pfizer CEO Jeff Kindler, after Dolsten delivered to his boss the unwelcome message, in 2009, that the turnaround of the drug giant’s research laboratories would be anything but rapid.

“I told him that, look, it’s not just one investment, it is like playing chess,’’ Dolsten recalled. “You need to have a picture of the entire opening game, win the middle game, and be really good in the end game. And it’s a marathon, Jeff, I told him.” Kindler left the meeting unhappy, but a few days later he appeared in Dolsten’s office with the chess set and his own words of wisdom: “Mikael, Pfizer needs a real chess player.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Who’s the opponent in the “chess match” here, who gets ‘checkmated?”

  • The company that was acquired by Pfizer in Michigan that delivered most of its blockbusters (Lipitor, Neurontin, Lyrica etc.) was Parke-Davis/Warner-Lambert and not Upjohn/Pharmacia. Pharmacia delivered celebrex.

  • Big question is “Are any of the drugs affordable by five+ million patients per year?” If not then they are for elite in a mutually subsidized healthcare system. They might have a value for the stockholders and that is it. So most writers are drooling saliva over money and others are pondering. Huh!

Comments are closed.